Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus

Leukemia. 2007 Nov;21(11):2384-5. doi: 10.1038/sj.leu.2404811. Epub 2007 Jun 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cell Proliferation
  • Chromosomes, Human, Pair 5*
  • Cytogenetics
  • Early Growth Response Protein 1 / genetics*
  • Gene Deletion
  • Humans
  • Lenalidomide
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Remission Induction
  • Stem Cell Transplantation / methods*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Time Factors
  • Transplantation, Homologous / methods*

Substances

  • Antineoplastic Agents
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Thalidomide
  • Lenalidomide